Compare HYPR & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYPR | ANIX |
|---|---|---|
| Founded | 2014 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 158.8M | 88.8M |
| IPO Year | 2021 | 2013 |
| Metric | HYPR | ANIX |
|---|---|---|
| Price | $1.42 | $2.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $1.59 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 749.5K | 158.6K |
| Earning Date | 05-12-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.21 | 12.82 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,563,000.00 | $210,000.00 |
| Revenue This Year | $50.75 | N/A |
| Revenue Next Year | $29.71 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.22 | N/A |
| 52 Week Low | $0.68 | $2.32 |
| 52 Week High | $2.22 | $5.46 |
| Indicator | HYPR | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 46.38 | 51.99 |
| Support Level | $1.39 | $2.38 |
| Resistance Level | $1.72 | $3.12 |
| Average True Range (ATR) | 0.10 | 0.19 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 17.19 | 61.54 |
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales, which consist of sales from subscriptions of bundled devices, maintenance, and software. The company is in the health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. The Company operates in one business segment, which includes all activities related to production, supply, service, and commercialization of the Swoop system.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.